Literature DB >> 26210671

Nicotine regulates the expression of UDP-glucuronosyltransferase (UGT) in humanized UGT1 mouse brain.

Masaya Sakamoto1, Tomoo Itoh2, Robert H Tukey3, Ryoichi Fujiwara4.   

Abstract

UDP-glucuronosyltransferase (UGT) is a family of enzymes that catalyze the glucuronidation of various compounds, and thereby has an important role in metabolism and detoxification of a large number of xenobiotic and endogenous compounds. UGTs are present highly in the liver and small intestine, while several investigations on quantification of UGT mRNA reported that UGTs were also expressed in the brain. However, reported expression patterns of UGT isoforms in human brain were often incongruous with each other. In the present study, therefore, we investigated UGT mRNA expressions in brains of humanized UGT1 (hUGT1) mice. We found that among the human UGT1 members, UGT1A1, 1A3, and 1A6 were expressed in the brain. We further observed that nicotine (3 mg/kg) induced the expression of UGT1A3 mRNA in the brain, but not liver. While it was not statistically significant, the nicotine treatment resulted in an increase in the chenodeoxycholic acid glucuronide-formation activity in the brain microsomes. UGT1A3 is involved in metabolism of various antidepressants and non-steroidal antiinflammatory drugs, which exhibit their pharmacological effects in the brain. Therefore, nicotine-treated hUGT1 mice might be useful to investigate the role of brain UGT1A3 in the regulation of local levels of these drugs and their response.
Copyright © 2015 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Brain; Humanized animal model; Nicotine; Tissue-specific regulation; UDP-glucuronosyltransferase (UGT)

Mesh:

Substances:

Year:  2015        PMID: 26210671      PMCID: PMC4752199          DOI: 10.1016/j.dmpk.2015.04.004

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  46 in total

1.  Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus.

Authors:  Q H Gong; J W Cho; T Huang; C Potter; N Gholami; N K Basu; S Kubota; S Carvalho; M W Pennington; I S Owens; N C Popescu
Journal:  Pharmacogenetics       Date:  2001-06

Review 2.  UGT genomic diversity: beyond gene duplication.

Authors:  Chantal Guillemette; Eric Lévesque; Mario Harvey; Judith Bellemare; Vincent Menard
Journal:  Drug Metab Rev       Date:  2010-02       Impact factor: 4.518

3.  Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes.

Authors:  M H Court; S X Duan; L M Hesse; K Venkatakrishnan; D J Greenblatt
Journal:  Anesthesiology       Date:  2001-01       Impact factor: 7.892

4.  Drug metabolism within the brain changes drug response: selective manipulation of brain CYP2B alters propofol effects.

Authors:  Jibran Y Khokhar; Rachel F Tyndale
Journal:  Neuropsychopharmacology       Date:  2010-11-24       Impact factor: 7.853

5.  Human UDP-glucuronosyltransferase (UGT) 2B10 in drug N-glucuronidation: substrate screening and comparison with UGT1A3 and UGT1A4.

Authors:  Yukiko Kato; Takeshi Izukawa; Shingo Oda; Tatsuki Fukami; Moshe Finel; Tsuyoshi Yokoi; Miki Nakajima
Journal:  Drug Metab Dispos       Date:  2013-04-23       Impact factor: 3.922

6.  In vitro morphine metabolism by rat microglia.

Authors:  Anna Rita Togna; Letizia Antonilli; Melania Dovizio; Adele Salemme; Lorenza De Carolis; Giuseppina I Togna; Paola Patrignani; Paolo Nencini
Journal:  Neuropharmacology       Date:  2013-08-27       Impact factor: 5.250

7.  Discovery of neurosteroid glucuronides in mouse brain.

Authors:  Sirkku E Kallonen; Anne Tammimäki; Petteri Piepponen; Helena Raattamaa; Raimo A Ketola; Risto Kostiainen
Journal:  Anal Chim Acta       Date:  2009-07-29       Impact factor: 6.558

8.  Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers.

Authors:  Takeshi Izukawa; Miki Nakajima; Ryoichi Fujiwara; Hiroyuki Yamanaka; Tatsuki Fukami; Masataka Takamiya; Yasuhiro Aoki; Shin-ichi Ikushiro; Toshiyuki Sakaki; Tsuyoshi Yokoi
Journal:  Drug Metab Dispos       Date:  2009-05-13       Impact factor: 3.922

9.  Formation of highly analgesic morphine-6-glucuronide following physiologic concentration of morphine in human brain.

Authors:  Hideyuki Yamada; Kumiko Ishii; Yuji Ishii; Ichiro Ieiri; Syunji Nishio; Takato Morioka; Kazuta Oguri
Journal:  J Toxicol Sci       Date:  2003-12       Impact factor: 2.196

10.  Presence of protein-bound unconjugated bile acids in the cytoplasmic fraction of rat brain.

Authors:  Nariyasu Mano; Takaaki Goto; Masashi Uchida; Koji Nishimura; Masayuki Ando; Norihiro Kobayashi; Junichi Goto
Journal:  J Lipid Res       Date:  2003-11-16       Impact factor: 5.922

View more
  4 in total

1.  Enzymatic analysis of glucuronidation of synthetic cannabinoid 1-naphthyl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FDU-PB-22).

Authors:  Sabrina Jones; Azure L Yarbrough; Amal Shoeib; John M Bush; William E Fantegrossi; Paul L Prather; Anna Radominska-Pandya; Ryoichi Fujiwara
Journal:  Xenobiotica       Date:  2019-03-20       Impact factor: 1.908

2.  Expression of UDP-Glucuronosyltransferase 1 (UGT1) and Glucuronidation Activity toward Endogenous Substances in Humanized UGT1 Mouse Brain.

Authors:  Yuki Kutsuno; Rika Hirashima; Masaya Sakamoto; Hiroko Ushikubo; Hirofumi Michimae; Tomoo Itoh; Robert H Tukey; Ryoichi Fujiwara
Journal:  Drug Metab Dispos       Date:  2015-05-07       Impact factor: 3.922

Review 3.  Species differences in drug glucuronidation: Humanized UDP-glucuronosyltransferase 1 mice and their application for predicting drug glucuronidation and drug-induced toxicity in humans.

Authors:  Ryoichi Fujiwara; Emiko Yoda; Robert H Tukey
Journal:  Drug Metab Pharmacokinet       Date:  2017-10-07       Impact factor: 3.614

Review 4.  Alterations of Cytochrome P450s and UDP-Glucuronosyltransferases in Brain Under Diseases and Their Clinical Significances.

Authors:  Yun Sheng; Hanyu Yang; Tong Wu; Liang Zhu; Li Liu; Xiaodong Liu
Journal:  Front Pharmacol       Date:  2021-04-21       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.